Use of aripiprazole in tardive dyskinesia: An open label study of six cases

Rajarethinam, Rajaprabhakaran; Dziuba, John; Manji, Suzanne; Pizzuti, Albert; Lachover, Leonard; Keshavan, Matcheri S.

doi:10.1080/15622970902995612

Cited by 16 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there are case reports (but no long‐term prospective studies) of improvement of TD after treatment with aripiprazole,9, 24, 26, 52–59 this may not be a prudent treatment strategy. Spontaneous, coincidental remission of TD rather than a true therapeutic effect of aripiprazole could explain this apparent therapeutic effect 14.…”

Section: Discussionmentioning

confidence: 99%

Tardive dyskinesia and other movement disorders secondary to aripiprazole

2010

View full text Add to dashboard Cite

The objective of this report is to draw attention to tardive dyskinesia (TD) caused by aripiprazole, a third generation antipsychotic. TD has been traditionally attributed to typical (first-generation) antipsychotics, but other dopamine receptor blocking drugs and atypical (second- and third-generation) neuroleptics are emerging as an important cause of TD. We reviewed the medical records of patients with TD seen at the Baylor College of Medicine Movement Disorders Clinic between 2002 and 2010 to identify patients with TD associated with aripiprazole. Among 236 patients with TD seen over the specified period, 8 (3.4%) were found to have aripiprazole-associated TD. In 5 patients, TD occurred after exclusive exposure to aripiprazole. The mean age at onset was 55.8 ± 14.8 years with a female predominance. The average duration of treatment with aripiprazole was 18.4 ± 26.4 months. Oro-bucco-lingual stereotypy was seen in all patients. In most patients, TD did not spontaneously improve after stopping aripiprazole. Of the 5 patients treated with tetrabenazine, 4 improved during follow-up. Although aripiprazole, a third generation antipsychotic, has been promoted to have a low risk of TD, the drug accounts for about 3.5% of patients with TD evaluated in a movement disorders clinic. This largest reported series draws attention to the growing incidence of TD and other drug-induced movement disorders associated with "atypical antipsychotics."

show abstract

Section: Discussionmentioning

confidence: 99%

Tardive dyskinesia and other movement disorders secondary to aripiprazole

2010

View full text Add to dashboard Cite

show abstract

“…These findings indicate that the 5-HT 1A partial agonist property of aripiprazole may mediate the drug's beneficial effect on dyskinetic movements61) and suggest that drugs targeting 5-HT 1A receptors provide a promising non-dopaminergic therapy for dyskinetic movement 60). Although several studies indicate that 5-HT 1A partial agonists decrease the incidence of extrapyramidal side effects, including tardive dyskinesia, evidence that they play a role in the remission of tardive dyskinesia is not convincing.…”

Section: Methodsmentioning

confidence: 96%

Tardive Dyskinesia: Treatment with Aripiprazole

Kang

Kim

2011

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Tardive dyskinesia is characterized by choreiform movements, or rhythmic abnormal involuntary movements of the face, mouth, tongue, trunk, and limbs. It is frequently associated with the use of neuroleptic medications. The choreiform movements are irreversible in some patients, even after the drug is withdrawn. Although no reliable treatment for tardive dyskinesia exists, atypical antipsychotics are associated with a significantly lower incidence of tardive dyskinesia than typical antipsychotics. Moreover, recent reports suggest that atypical antipsychotics may have a beneficial effect on tardive dyskinesia remission. Until recently, evidence for the effectiveness of aripiprazole on tardive dyskinesia has been mixed. Aripiprazole has a unique mechanism of action and has various effects in tardive dyskinesia. The drug acts as a partial D2 receptor agonist that can stabilize D2 up-regulation, and as a partial 5-HT1A receptor agonist and a 5-HT2A receptor antagonist, and can increase the release of dopamine in the striatum.

show abstract

“…[4] There have been reports of aripiprazole being used in patients with TD, resulting in reductions in symptoms of TD. [5,6] As aripiprazole has been reported to normalize dopamine D2 up-regulation, the antipsychotic may improve the symptoms of TD-induced by typical or atypical, antipsychotics. [7] Rapid dissociation of aripiprazole also appears to be responsible for its low potential to cause TD.…”

Section: Discussionmentioning

confidence: 99%

Aripiprazole in Tardive Dyskinesia: Is it a Safe Choice?

Doval

Das

Moun

2017

Journal of Neurosciences in Rural Practice

View full text Add to dashboard Cite

Tardive dyskinesia (TD) is a potentially irreversible drug-induced movement disorder associated with prolonged administration of antipsychotics. Conventionally, first generation antipsychotics were the agents thought to have a higher risk of TD as compared to second and third generation antipsychotics. Aripiprazole is a third generation antipsychotic with a novel mechanism of action, and until recently, cases of drug-induced movement disorders were less well known with it. But off late, several cases of TD with aripiprazole have been reported. We present here a case of middle-aged women with preexisting tardive movements, which exacerbated with aripiprazole use and reduced in frequency and intensity on withdrawal of the drug.

show abstract

Use of aripiprazole in tardive dyskinesia: An open label study of six cases

Cited by 16 publications

References 15 publications

Tardive dyskinesia and other movement disorders secondary to aripiprazole

Tardive dyskinesia and other movement disorders secondary to aripiprazole

Tardive Dyskinesia: Treatment with Aripiprazole

Aripiprazole in Tardive Dyskinesia: Is it a Safe Choice?

Contact Info

Product

Resources

About